================================================================================
CONSOLIDATED ACTION PLAN: NEXT 12 MONTHS
================================================================================

WEEK 1 PRIORITIES (IMMEDIATE):
├─ Assign Regulatory Affairs Lead (FTE ≥0.5) → begin Pre-IND package drafting
├─ Begin Multi-HLA Epitope Mapping (DR4, DQ2, DQ8, DQ5 via IEDB)
├─ Contact FDA OOD for Pre-IND Meeting Scheduling (aim month 10-12)
├─ Initiate Manufacturing CMO Outreach (identify NP conjugation capacity)
└─ Recruit Phase 1 Patient Cohort & Finalize Study Protocol

MONTH 1-3: FOUNDATIONAL WORKSTREAMS
├─ Pre-IND Package Development (120 pages: CMC, nonclinical, Phase 1 design)
├─ Multi-HLA Epitope Design (structural modeling for DR4, DQ2, DQ8, DQ5)
├─ Manufacturing CMO Scouting (bench-scale conjugation, CPP identification)
├─ Phase 1 Study Protocol Finalization (ex vivo n=20 + in vivo exploratory n=5-10)
├─ Immunogenicity Assessment Plan (anti-pMHC, anti-NP IgE/IgG/IgA monitoring)
└─ Companion Diagnostic Feasibility Study (HLA genotyping + responder biomarker)

MONTH 4-6: EXECUTION & REGULATORY SUBMISSION
├─ Pre-IND Package Submission to FDA (month 6 target)
├─ Manufacturing Process Optimization (NP yield, stoichiometry, stability)
├─ Phase 1 IRB Submission & Patient Recruitment (month 5-6)
├─ Extended Phase 3 GLP Study Design (6-month biodegradation + iron quantification)
└─ Breakthrough Designation Application (prep for Phase 1 interim data, month 9-12)

MONTH 7-12: PHASE 1 INITIATION & REGULATORY ENGAGEMENT
├─ Phase 1 Interim Data Collection (ex vivo assay, months 8-10; in vivo n=1-3, months 10-12)
├─ FDA Pre-IND Meeting (month 10, expected; feedback month 10-11)
├─ IND Package Assembly (based on FDA feedback, months 11-12)
├─ Breakthrough Designation Submission (month 12, contingent on Phase 1 interim signal)
├─ Manufacturing Pilot Batch Release (Phase 4 gate: ≥50% yield, month 12)
└─ Biotech Licensing Discussions Initiation (leverage Phase 1 interim + multi-HLA roadmap)

MONTH 13-18: PHASE 1 COMPLETION & PHASE 2 PLANNING
├─ Phase 1 Final Data Analysis (ex vivo + in vivo eosinophil reduction, immunogenicity)
├─ Dairy Epitope Manuscript Submission (Nature Immunology / Nature Communications)
├─ IND Submission to FDA (month 18, assuming Pre-IND feedback + Phase 1 final data)
├─ Phase 2 Mouse EoE Model Initiation (months 16-27)
└─ Multi-HLA Epitope Package Finalization (DR4, DQ2, DQ8, DQ5 formats + manufacturing ready)

MONTH 19-24: PHASE 1/2 PARALLEL & PHASE 3 PRECLINICAL
├─ Phase 2 Interim Data (eosinophil count reduction, Tr1 expansion, months 20-24)
├─ GLP Toxicology & Extended Biodegradation Studies (months 19-24)
├─ IND Amendment (Phase 2 interim data, multi-HLA expansion plan, months 22-24)
├─ Manufacturing GMP Campaign Planning (Phase 4 scope finalized based on Phase 2 go-gate)
└─ Biotech Partnership Finalization (licensing, manufacturing strategy, clinical roadmap)

MONTH 25+: TRANSITION TO BIOTECH PARTNERSHIP & REGULATORY PATHWAY
├─ Technology Transfer to Biotech Partner (manufacturing, clinical protocols)
├─ Phase 2 Completion & Phase 3 IND Amendment
├─ Full Therapeutic Design Manuscript Submission (Science Translational Medicine / eLife)
└─ Clinical-Stage Regulatory Preparation (Phase 3 design, safety database assembly)

================================================================================
CRITICAL GATES & GO/NO-GO CRITERIA
================================================================================

PHASE 1 GO-GATE (Month 12):
✓ Dairy: ≥50% of patients achieve CD39+CD73+ IL-10+ Tr1 expansion (target frequency ≥1-2%)
✓ Wheat/Soy: ≥30% response (IL-10 ELISPOT or TCR+ expansion); if <30%, switch to DR4/DQ2 variants for Phase 2
✓ Safety: No serious adverse events in ex vivo or in vivo arms; anti-NP IgE present but <20% of patients
✓ Immunogenicity: No dose-limiting anti-pMHC antibodies; tolerability acceptable for Phase 1b expansion
✓ Manufacturing: Pilot batch ≥50% yield, stoichiometry within ±20% of target
→ DECISION: Proceed to Phase 1b (in vivo) or Phase 2 (BALB/c EoE model)

PHASE 1B/2 GO-GATE (Month 21):
✓ Phase 1 in vivo: Esophageal eosinophil count reduction ≥30% in ≥50% of patients (n=5-10)
✓ Phase 2 mouse: BALB/c EoE sensitization successful; pMHC-NP treatment reduces eosinophil count ≥40% vs. placebo
✓ Tr1 correlation: CD39+CD73+ expansion correlates with eosinophil reduction (R² ≥0.6)
✓ Immunogenicity: No IgE-mediated anaphylaxis; anti-NP antibodies do not prevent repeat dosing
→ DECISION: Proceed to Phase 3 (GLP tox, extended biodegradation) and Phase 4 (GMP)

PHASE 3 GO-GATE (Month 24):
✓ GLP Safety: No dose-limiting organ toxicity; spleen/liver/kidney iron quantification acceptable (<100 μg Fe/g organ at 28d)
✓ Biodegradation: Iron clearance kinetics support annual or less-frequent dosing schedule
✓ CMC/GMP: Pilot batch meets all specifications; scale-up plan validated for cGMP manufacturing
→ DECISION: Proceed to Phase 4 (GMP manufacturing) and IND submission

NO-GO TRIGGERS (Any of these halt development; consider pivot strategy):
✗ Phase 1 ex vivo: Dairy IL-10 response <20% of patients (insufficient Tr1 induction mechanism)
✗ Phase 1 in vivo: Safety signal (anaphylaxis, organ toxicity, unexplained fever)
✗ Phase 2 mouse: Eosinophil reduction <10% (efficacy insufficient); or Tr1 induction reverses without continued dosing (durability failure)
✗ Manufacturing: Yield <5 mg/L or stoichiometry CV >40% (scale-up infeasible); CMO unable to deliver
✗ FDA Pre-IND: Regulatory pathway deemed infeasible (e.g., device CMC too expensive relative to market); pivot to academic/non-profit path

CONTINGENCY PIVOTS (If No-Go triggered):
— Dairy only (single-epitope product): publish, license to diagnostic partner; de-prioritize therapeutic development
— Alternative modality: single-chain instead of NP (easier manufacturing); tetramer for ex vivo diagnostics
— Alternative scaffold: non-iron-oxide (VLP, albumin NP, lipid nanoparticle); different CMO partnership
— Alternative mechanism: adjuvant-based (IL-15, IL-33 co-stimulation) instead of Tr1 alone
— Academic collaboration: non-profit development path (NIH grants, university partnership) instead of biotech licensing

================================================================================
BUDGET SUMMARY (18-24 MONTHS): CORRECTED & RECONCILED TOTALS
================================================================================

**PHASE 1 (8-12 weeks): $20-35k**
├─ Ex vivo assay setup & patient recruitment: $10-15k
├─ In vivo exploratory dosing (n=5-10): $5-10k
└─ Immunogenicity + companion diagnostic feasibility: $5-10k
└─→ **PHASE 1 SUB-TOTAL: $20-35k** ✓

**PHASE 2 (12 weeks): $35-55k**
├─ BALB/c sensitization protocol & eosinophil assessment: $20-30k
├─ Valency optimization arm (3/5/8 pMHC/NP): $10-15k
└─ Tr1 marker profiling & correlation analysis: $5-10k
└─→ **PHASE 2 SUB-TOTAL: $35-55k** ✓

**PHASE 3 (12-16 weeks): $105-170k**
├─ Standard 28-day GLP acute tox: $60-100k
├─ Extended biodegradation studies (6-month timescale): $40-60k
└─ Iron quantification (Prussian blue, ICP-AES): $5-10k
└─→ **PHASE 3 SUB-TOTAL: $105-170k** ✓

**PHASE 4 (16-26 weeks): $80-140k**
├─ GMP scale-up & pilot batch release: $40-70k
├─ Device-track CMC (if required by FDA): $30-50k
└─ Stability & analytical method validation: $10-20k
└─→ **PHASE 4 SUB-TOTAL: $80-140k** ✓

**PHASE 5 (8-12 weeks): $15-27k**
├─ IND dossier assembly & Pre-IND package: $8-12k
├─ Breakthrough designation application: $2-5k
└─ FDA interaction & regulatory strategy consulting: $5-10k
└─→ **PHASE 5 SUB-TOTAL: $15-27k** ✓

================================================================================
**GRAND TOTAL (ALL PHASES): $255-427k**

Breakdown (reconciled):
- Phase 1: $20-35k
- Phase 2: $35-55k
- Phase 3: $105-170k
- Phase 4: $80-140k
- Phase 5: $15-27k
- **TOTAL: $20+35+105+80+15 = $255k (minimum)**
- **TOTAL: $35+55+170+140+27 = $427k (maximum)**

---

### BUDGET CLARIFICATION

The original estimated range ($195-355k base) was incomplete because it did not fully itemize:
- Phase 1b in vivo exploratory arm ($5-10k)
- Phase 3 extended biodegradation studies ($40-60k)
- Phase 4 FDA device-track CMC contingency ($30-50k)
- Phase 5 regulatory consulting ($5-10k)

The true **all-in preclinical roadmap cost is $255-427k** (18-24 months).

### Cost Reduction Opportunities:

- Academic collaborators for preclinical work (mouse, GLP) = 20-30% cost reduction
- Multi-HLA design in parallel (not sequential) = saves 4-6 weeks, no additional cost
- Non-profit regulatory consulting vs. commercial RA firm = saves $10-20k
- Public dataset mining for Phase 2 validation = secondary endpoint enrichment, no cost

================================================================================